NYU Langone Health: Multiple Sclerosis trials

The registry lists 27 Multiple Sclerosis studies with NYU Langone Health as lead sponsor. 2 are open to participants now and 10 have results posted.

Phase 2 2Phase 4 1No phase 24(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Care in Multiple Sclerosis (MS)RecruitingNCT07011914
• Home-Based Transcranial Direct Current Stimulation (tDCS) for Depression in Multiple Sclerosis (MS)RecruitingNCT06901687Phase 2
• Cognitive Markers in Prodromal MSCompletedNCT05543915Not applicableResults posted
• RELAXaHEAD for Headache Patients (Phase II)CompletedNCT05466682Not applicableResults posted
• A Teleheath tDCS Approach to Decrease Cannabis UseCompletedNCT05005013Phase 2Results posted
• Combined Effect of Transcranial Direct Current Stimulation (tDCS) and Physical Activity on Gait and Functional Mobility in Participants With Multiple SclerosisCompletedNCT03658668Not applicableResults posted
• Virtual Reality (VR) to Improve Quality of Life in Patients Diagnosed With Neurological DisordersCompletedNCT03606668Not applicableResults posted
• Assessment of tDCS-Induced Neuronal Responses in Multiple Sclerosis (MS) With Advanced MRICompletedNCT03564496Not applicableResults posted
• A Pilot Trial of Remotely-Supervised Transcranial Direct Current Stimulation (RS-tDCS) to Enhance Motor Learning in Progressive Multiple Sclerosis (MS)CompletedNCT03499314Not applicableResults posted
• Cognitive Remediation Augmented With Transcranial Direct Current Stimulation (tDCS)TerminatedNCT03049969Not applicableResults posted
• Pilot Study of Transcranial Direct Current Stimulation (tDCS)CompletedNCT02746705Not applicableResults posted
• Single Center, Open Label, Study of Preparation H on Erythema in Relapsing MS Patients Treated With PLEGRIDYTerminatedNCT02665221Phase 4Results posted
• Noninvasive Vagal Nerve StimulationActive, not recruitingNCT06816004Not applicable
• At-Home Gait AssessmentCompletedNCT05724901
• Symptom Burden in Patients Treated With Ocrelizumab for Multiple SclerosisCompletedNCT04855617
• Vaccine-generated Immunity in Ocrelizumab-treated Patients: Longitudinal Assessments (VIOLA)CompletedNCT04843774
• Estimating Prevalence of COVID-19 Infection and SARS-CoV-2 Antibodies in MS PatientsCompletedNCT04682548
• TRPMS to Improve Mobility and Depression in Multiple SclerosisWithdrawnNCT04578041Not applicable
• Endeavor™ in Pediatric MSWithdrawnNCT04445116Not applicable
• Mobile Attentional Bias Modification Training in Pediatric MSCompletedNCT04441229Not applicable
• tDCS for the Management of Multiple Sclerosis Related FatigueCompletedNCT03838770Not applicable
• Linking Cognitive Functioning to Multimodal Imaging in Multiple Sclerosis (MS)TerminatedNCT03723356
• RELAXaHEAD for Headache Patients (Phase I)CompletedNCT03183791Not applicable
• A Study to Analyze the Effect of Acupuncture on Mobility And Quality of Life in Multiple SclerosisCompletedNCT03174379Not applicable
• pH-weighted MRI in Multiple Sclerosis: A Surrogate Marker of Tissue Metabolic StressCompletedNCT03028675
• Impact of CRISP on Self-Efficacy, Loneliness, and DepressionCompletedNCT02030197Not applicable
• Quantitative Imaging and Proton Spectroscopy in Multiple SclerosisTerminatedNCT01226654Not applicable